5 Value Stocks To Watch In The Healthcare Sector
Portfolio Pulse from Benzinga Insights
The article lists 5 healthcare sector value stocks with low P/E ratios, suggesting they may be undervalued: CalciMedica (CALC), Quoin Pharmaceuticals (QNRX), SCYNEXIS (SCYX), Syros Pharmaceuticals (SYRS), and Organon (OGN). It provides their P/E ratios and recent earnings per share (EPS) data, noting changes from the previous quarter. Organon also reported an increased dividend yield. The article cautions that value stocks may take time to rebound and there's a risk they may not.
January 29, 2024 | 2:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CalciMedica is highlighted as a value stock with a very low P/E of 0.07 and an improvement in EPS from Q2 to Q3.
The improvement in EPS and extremely low P/E ratio could attract investors looking for undervalued stocks, potentially driving up the short-term price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 90
POSITIVE IMPACT
Organon is noted for its P/E of 7.34, a decrease in EPS from Q2, but an increased dividend yield, which may attract dividend investors.
The increased dividend yield could compensate for the lower EPS, potentially attracting investors focused on income, which may lead to a positive short-term price impact.
CONFIDENCE 75
IMPORTANCE 75
RELEVANCE 85
POSITIVE IMPACT
Quoin Pharmaceuticals is considered undervalued with a P/E of 2.62 and an improvement in its EPS from Q2 to Q3.
The low P/E ratio and improved EPS indicate potential undervaluation, which may lead to increased investor interest and a positive short-term price impact.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 90
NEGATIVE IMPACT
SCYNEXIS has a low P/E of 1.26 but experienced a decrease in EPS from Q2 to Q3, which may concern investors.
Despite the low P/E, the decrease in EPS could be a negative signal to investors, potentially leading to a short-term decline in stock price.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 80
NEGATIVE IMPACT
Syros Pharmaceuticals, with a P/E of 8.08, reported a 10% decrease in EPS from Q2 to Q3, which may not appeal to investors.
The decrease in EPS could overshadow the relatively low P/E ratio, potentially leading to a negative short-term price movement.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 80